RegenXBio Inc. (RGNX)
NASDAQ:RGNX
Want to see RGNX full AI Analyst Report?
RGNX Stock Chart & Stats
$9.49
-$0.26(-3.11%)
At close: 4:00 PM EST
$9.49
-$0.26(-3.11%)
Day’s Range― - ―
52-Week Range$5.46 - $16.19
Previous CloseN/A
Volume155.59K
Average Volume (3M)1.83M
Market Cap
$344.31M
Enterprise Value$418.24M
Total Cash (Recent Filing)$150.49M
Total Debt (Recent Filing)$71.07M
Price to Earnings (P/E)―
Beta2.43
Next Earnings
Aug 05, 2026EPS Estimate
0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.60
Shares Outstanding51,697,620
10 Day Avg. Volume1,313,963
30 Day Avg. Volume1,833,083
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)7.23
Price to Sales (P/S)4.36
P/FCF Ratio-5.88
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue4.76
Enterprise Value/Gross Profit-3.49K
Enterprise Value/Ebitda-1.82
Forecast
1Y Price Target
$19.50Price Target Upside105.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.85
Revenue Forecast (FY)$234.86M
Bulls Say, Bears Say
Bulls Say
NAV AAV Platform & Licensing ModelThe NAV AAV platform underpins a durable licensing business: upfronts, R&D funding, milestones and royalties provide non-product revenue streams. Broad partner adoption lets RegenX capture value while externalizing much clinical risk, supporting steady long-term cash inflows when milestones hit.
Pivotal Phase III Success (RGX-202)Meeting the pivotal primary endpoint materially de-risks RGX-202's development path and supports the company's stated accelerated approval strategy. Durable impact: a validated pivotal outcome increases the probability of regulatory progress, shortens time-to-commercial-readiness if surrogate acceptance holds, and strengthens partner/commercial planning.
Strategic Partnerships & Near-Term MilestonesA $100M AbbVie milestone and multiple partner programs validate NAV tech and provide material non-dilutive funding upon achievement. Durable benefit comes from confirmed partner commitments that both validate the platform commercially and can extend cash runway as the company advances pivotal/commercial planning.
Bears Say
Heavy Cash BurnSustained negative operating and free cash flow creates ongoing financing pressure. Over the next 2-6 months the company will likely need milestone receipts or capital markets access to fund operations, increasing dilution or covenant risk and constraining investment optionality for commercialization and manufacturing scale-up.
High Leverage & Thin EquityMaterial leverage and a very thin equity base weaken financial resilience. High debt-to-equity limits flexibility for additional borrowing, raises refinancing risk if clinical timelines slip, and amplifies dilution risks from future equity raises needed to fund late-stage trials or to commercialize approved products.
Regulatory & Data UncertaintyRegulatory insistence on randomized controls or rejection of external-control strategies could force larger, longer trials and materially delay approval timelines. That structural risk raises program cost, defers revenue and increases capital needs, undermining the near-term commercialization case even with positive biomarker signals.
RegenXBio News
RGNX FAQ
What was RegenXBio Inc.’s price range in the past 12 months?
RegenXBio Inc. lowest stock price was $5.46 and its highest was $16.19 in the past 12 months.
What is RegenXBio Inc.’s market cap?
RegenXBio Inc.’s market cap is $344.31M.
When is RegenXBio Inc.’s upcoming earnings report date?
RegenXBio Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 50 days.
How were RegenXBio Inc.’s earnings last quarter?
RegenXBio Inc. released its earnings results on May 14, 2026. The company reported -$1.72 earnings per share for the quarter, missing the consensus estimate of -$1.337 by -$0.383.
Is RegenXBio Inc. overvalued?
According to Wall Street analysts RegenXBio Inc.’s price is currently Undervalued.
Does RegenXBio Inc. pay dividends?
RegenXBio Inc. does not currently pay dividends.
What is RegenXBio Inc.’s EPS estimate?
RegenXBio Inc.’s EPS estimate is 0.25.
How many shares outstanding does RegenXBio Inc. have?
RegenXBio Inc. has 51,697,620 shares outstanding.
What happened to RegenXBio Inc.’s price movement after its last earnings report?
RegenXBio Inc. reported an EPS of -$1.72 in its last earnings report, missing expectations of -$1.337. Following the earnings report the stock price went down -37.799%.
Which hedge fund is a major shareholder of RegenXBio Inc.?
Currently, no hedge funds are holding shares in RGNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RegenXBio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.50 (105.48% Upside)
$19.50 (105.48% Upside)
Blogger Sentiment
Bullish
RGNX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 329.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.70%
12-Months-Change
Fundamentals
Return on Equity
-232.50%
Trailing 12-Months
Asset Growth
-30.36%
Trailing 12-Months
Company Description
RegenXBio Inc.
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
RGNX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a notably positive clinical and programmatic update: RGX-202 met its pivotal primary endpoint with high biomarker expression, demonstrated an unusually strong correlation between microdystrophin and functional benefit (>0.9), and showed encouraging interim safety and functional signals with plans for potential accelerated approval in 2027. Key operational and regulatory risks were acknowledged — chiefly the limited number of mature 12‑month functional datapoints so far, reliance on external controls (and FDA concern about bias), and the possibility that the agency could request randomized trials which would materially delay approval. Remaining uncertainties on long‑term durability and the logistical burden of the prophylaxis regimen were also discussed. Overall the clinical readout and pipeline progress meaningfully outweigh near‑term risks, but regulatory process and more mature datasets remain critical next milestones.View all RGNX earnings summariesRGNX Stock 12 Month Forecast
Average Price Target
$19.50
▲(105.48% Upside)
Technical Analysis
Solid Biosciences
―
Monopar Therapeutics Inc
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
8.91% Insiders
17.37% Mutual Funds
20.55% Other Institutional Investors
38.11% Public Companies and
Individual Investors